Typically, companies have 180 days to regain compliance. However, CNS is ineligible for this extension due to previous reverse stock splits totaling a 250-to-1 ratio over the past two years.
As a result, the company has requested a hearing, scheduled for November 5, which temporarily delays any delisting actions.
Per a Wednesday SEC filing, CNS Pharmaceuticals says there’s no guarantee of an additional extension being granted.
Read Also: Tesla Stock Faces Selling Pressure Ahead Of Q3 Earnings: 4 Takeaways From The Chart
According to data from Benzinga Pro, CNSP has a 52-week high of $137.50 and a 52-week low of $0.09.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
